| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8133893 | ANGELINI PHARMA | Trazodone and trazodone hydrochloride in purified form |
Mar, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6607748 | ANGELINI PHARMA | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture |
Jun, 2020
(3 years ago) | |
| US7829120 | ANGELINI PHARMA | Trazodone composition for once a day administration |
Mar, 2027
(2 years from now) | |
Oleptro is owned by Angelini Pharma.
Oleptro contains Trazodone Hydrochloride.
Oleptro has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Oleptro are:
- US6607748
Oleptro was authorised for market use on 02 February, 2010.
Oleptro is available in tablet, extended release;oral dosage forms.
Oleptro can be used as method of treating depression.
The generics of Oleptro are possible to be released after 13 March, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Feb 02, 2013 |
Drugs and Companies using TRAZODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 02 February, 2010
Treatment: Method of treating depression
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of OLEPTRO before it's drug patent expiration?
More Information on Dosage
OLEPTRO family patents
